Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 202: Sotorasib plus platinum doublet vs pembrolizumab plus platinum doublet in PD-L1–negative KRAS p.G12C nonsquamous NSCLC
2022-501863-41-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival (PFS). Planned start Oct 2023; status: authorised.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501863-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501863-41-00.